Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25832
Title: Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi.
Austin Authors: Merli, Francesco;Luminari, Stefano;Tucci, Alessandra;Arcari, Annalisa;Rigacci, Luigi;Hawkes, Eliza A ;Chiattone, Carlos S;Cavallo, Federica;Cabras, Giuseppina;Alvarez, Isabel;Fabbri, Alberto;Re, Alessandro;Puccini, Benedetta;Barraclough, Allison ;Delamain, Marcia Torresan;Ferrero, Simone;Usai, Sara Veronica;Ferrari, Angela;Cencini, Emanuele;Pennese, Elsa;Zilioli, Vittorio Ruggero;Marino, Dario;Balzarotti, Monica;Cox, Maria Christina;Zanni, Manuela;Di Rocco, Alice;Lleshi, Arben;Botto, Barbara;Hohaus, Stefan;Merli, Michele;Sartori, Roberto;Gini, Guido;Nassi, Luca;Musuraca, Gerardo;Tani, Monica;Bottelli, Chiara;Kovalchuk, Sofia;Re, Francesca;Flenghi, Leonardo;Molinari, Annalia;Tarantini, Giuseppe;Chimienti, Emanuela;Marcheselli, Luigi;Mammi, Caterina;Spina, Michele
Affiliation: Hematology Unit, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy
Olivia Newton-John Cancer Research Institute
Clinical Haematology
Samaritano Hospital, Sao Paulo, Brazil
Santa Casa Medical School, Sao Paulo, Brazil
Department CHIMOMO, University of Modena and Reggio Emilia, Reggio Emilia, Italy
Hematology Unit, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy
Hematology Division, ASST Spedali Civili Brescia, Brescia, Italy
Hematology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy
Haematology Unit, Careggi University Hospital, Firenze, Italy
Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino/AOU "Città della Salute e della Scienza di Torino," Torino, Italy
Division of Hematology, Ospedale Oncologico Armando Businco, Cagliari, Italy
Hematology Unit, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy
Unit of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena, Siena, Italy
Hematology Division, ASST Spedali Civili Brescia, Brescia, Italy
Haematology Unit, Careggi University Hospital, Firenze, Italy
Hemocentro-Unicamp, University of Campinas, Campinas, Brazil
Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino/AOU "Città della Salute e della Scienza di Torino," Torino, Italy
Division of Hematology, Ospedale Oncologico Armando Businco, Cagliari, Italy
Hematology Unit, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy
Unit of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena, Siena, Italy
Lymphoma Unit, Department of Hematology, Ospedale Spirito Santo, Pescara, Italy
Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
Department of Medical Oncology and Hematology, Humanitas Clinical Research Hospital-IRCCS, Rozzano (MI), Italy
Hematology Unit, Azienda Ospedaliera Universitaria Sant'Andrea, Roma, Italy
Hematology Unit, Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy
Institute of Hematology, Department of Translational and Precision Medicine "Sapienza," University of Roma, Roma, Italy
Division of Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy
Division of Hematology, Città della Salute e della Scienza Hospital and University, Torino, Italy
University Policlinico Gemelli Foundation-IRCCS, Catholic University of the Sacred Heart, Roma, Italy
Division of Hematology, Ospedale di Circolo e Fondazione Macchi-ASST Sette Laghi, University of Insubria, Varese, Italy
Department of Clinical and Experimental Oncology, Oncohematology Unit, Veneto Institute of Oncology, IOV-IRCCS, Castelfranco Veneto (TV), Italy
Division of Hematology, Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona, Italy
Hematology, AOU Maggiore della Carità and University of Eastern Piedmont, Novara, Italy
Hematology Unit, IRCCS-Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) SRL, Meldola (FC), Italy
Hematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy
Hematology Division, ASST Spedali Civili Brescia, Brescia, Italy
Haematology Unit, Careggi University Hospital, Firenze, Italy
Hematology and BMT Center, Azienda Ospedaliera Universitaria, Parma, Italy
Hematology, Santa Maria della Misericordia Hospital, Perugia, Italy
Hematology Unit, Ospedale degli Infermi, Rimini, Italy
Haematology and BMT Unit, Ospedale Monsignor R. Dimiccoli, Barletta, Italy
Division of Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy
Fondazione Italiana Linfomi Onlus, Modena, Italy
Gruppo Amici dell'Ematologia GRADE-Onlus Foundation, Reggio Emilia, Italy
Division of Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy
Issue Date: Nov-2021
Date: 2021-02-12
Publication information: Journal of Clinical Oncology 2021; 39(11): 1214-1222
Abstract: To prospectively validate the use of a simplified geriatric assessment (sGA) at diagnosis and to integrate it into a prognostic score for older patients with diffuse large B-cell lymphoma (DLBCL). We conducted the prospective Elderly Project study on patients with DLBCL older than 64 years who underwent our Fondazione Italiana Linfomi original geriatric assessment (oGA) (age, Cumulative Illness Rating Scale for Geriatrics, activities of daily living, and instrumental activities of daily living) before treatment. Treatment choice was left to the physician's discretion. The primary end point was overall survival (OS) (ClinicalTrials.gov identifier: NCT02364050). We analyzed 1,163 patients (median age 76 years), with a 3-year OS of 65% (95% CI, 62 to 68). Because at multivariate analysis on oGA, age > 80 years retained an independent correlation with OS, we also developed a new, simplified version of the GA (sGA) that classifies patients as fit (55%), unfit (28%), and frail (18%) with significantly different 3-year OS of 75%, 58%, and 43%, respectively. The sGA groups, International Prognostic Index, and hemoglobin levels were independent predictors of OS and were used to build the Elderly Prognostic Index (EPI). Three risk groups were identified: low (23%), intermediate (48%), and high (29%), with an estimated 3-year OS of 87% (95% CI, 81 to 91), 69% (95% CI, 63 to 73), and 42% (95% CI, 36 to 49), respectively. The EPI was validated using an independent external series of 328 cases. The Elderly Project validates sGA as an objective tool to assess fitness status and defines the new EPI to predict OS of older patients with DLBCL.
URI: https://ahro.austin.org.au/austinjspui/handle/1/25832
DOI: 10.1200/JCO.20.02465
ORCID: 0000-0002-0979-7883
0000-0002-9320-9334
0000-0002-0376-2559
0000-0002-4639-2578
0000-0003-2603-9715
0000-0003-1615-0540
0000-0001-9071-4397
0000-0002-9711-1502
0000-0002-9984-1146
0000-0003-4666-5115
0000-0002-5534-7197
0000-0002-0905-5927
0000-0003-1947-1032
0000-0002-4610-3289
0000-0001-6576-8182
Journal: Journal of Clinical Oncology
PubMed URL: 33577377
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

120
checked on Oct 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.